Merja Soilu-Hänninen
MD, PhD
Turku University Hospital, Division of Clinical Neurosciences mersoi@utu.fi ORCID identifier: https://orcid.org/0000-0001-6930-0229 |
Clinical neurology; neuroimmunology; multiple sclerosis risk factors, prognostic factors and treatment
MD, University of Turku 1988
PhD, University of Turku, Department of Virology, Immunobiology of central nervous system virus infections 1996
Postdoctoral Fellow, Development and Neurobiology Group, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 1997-1999
Specialist Degree in Neurology 2001
Adjuct Professor of Clinical Neurology 2008
Inverstigator in several clinical MS trials
Chair of the Finnish MS registry 2016-
General Neurology Section Head, Turku University Hospital, Division of Clinical Neurosciences 2017-
Multiple sclerosis risk factors, prognostic factors and epidemiology.
Imaging of brain atrophy in multiple sclerosis.
Course of medical pedagogics 2011-2012
Supervisor of several PhD student
- Miksi MS-tauti yleistyy? (2022)
- Duodecim
(A2 Refereed review article in a scientific journal ) - MS-taudin ja liikehäiriöiden laaturekisterit (2022)
- Erikoislääkäri
(D1 Article in a professional journal) - Neurosarkoidoosin uudistunut diagnostiikka ja tehostunut hoito (2021)
- Duodecim
(A2 Refereed review article in a scientific journal ) - Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis (2020)
- Dosis
(A1 Refereed original research article in a scientific journal) - Changes in multiple sclerosis epidemiology in Finland over five decades (2020)
- Acta Neurologica Scandinavica
(A2 Refereed review article in a scientific journal ) - Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients (2020)
- Journal of Neuroimmune Pharmacology
(B1 Non-refereed article in a scientific journal) - Medication adherence/persistence among patients with active multiple sclerosis in Finland (2020)
- Acta Neurologica Scandinavica
(A1 Refereed original research article in a scientific journal) - Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis (2020)
- Frontiers in Neurology
(A1 Refereed original research article in a scientific journal) - Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009–2018 (2020)
- Multiple Sclerosis and Related Disorders
(A1 Refereed original research article in a scientific journal) - Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients (2020)
- Brain and Behavior
(A1 Refereed original research article in a scientific journal)



